Literature DB >> 15297071

Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (Differentiating Infected from Vaccinated Animals) strategy for the control of avian influenza.

Chang-Won Lee1, Dennis A Senne, David L Suarez.   

Abstract

Vaccination of poultry with inactivated influenza vaccine can be an effective tool in the control of avian influenza (AI). One major concern of using inactivated vaccine is vaccine-induced antibody interference with serologic surveillance and epidemiology. In the United States, low pathogenicity H5 and H7 subtype AI viruses have caused serious economic losses in the poultry industry. Most of these viruses also have the accompanying N2 subtype and no H5N1 or H7N8 subtype AI viruses have been identified in poultry in the US. In order to allow the Differentiation of Infected from Vaccinated Animals (DIVA) while maintaining maximum efficacy of the vaccine, we generated reassortant viruses by reverse genetics that contained the same H5 and H7 hemagglutinin (HA) gene as the challenge virus, but a heterologous N1 or N8 neuraminidase (NA) gene. In vaccination-challenge experiments in 2-week-old specific pathogen free chickens, reassortant influenza vaccines (rH5N1 and rH7N8) demonstrated similar antibody profiles and comparable protection rates as vaccines prepared with parent H5N2 and H7N2 viruses. Further, we were able to differentiate the sera from infected and vaccinated birds by neuraminidase inhibition test and indirect immunofluorescent antibody assay on the basis of different antibodies elicited by their NA proteins. These results demonstrate the usefulness of a reverse genetics system for the rapid generation of reassortant AI virus that allows utilization of the DIVA strategy for the control of AI infections in poultry.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297071     DOI: 10.1016/j.vaccine.2004.01.055

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.

Authors:  Shixia Wang; Jessica Taaffe; Christopher Parker; Alicia Solórzano; Hong Cao; Adolfo García-Sastre; Shan Lu
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

2.  Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector.

Authors:  Haroldo Toro; De-chu C Tang; David L Suarez; Matt J Sylte; Jennifer Pfeiffer; Kent R Van Kampen
Journal:  Vaccine       Date:  2006-09-25       Impact factor: 3.641

3.  A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1.

Authors:  Jacob Schön; Wei Ran; Marco Gorka; Martin Schwemmle; Martin Beer; Donata Hoffmann
Journal:  NPJ Vaccines       Date:  2020-05-15       Impact factor: 7.344

4.  Avian influenza vaccination in chickens and pigs with replication-competent adenovirus-free human recombinant adenovirus 5.

Authors:  Haroldo Toro; Frederik W van Ginkel; De-Chu C Tang; Bettina Schemera; Soren Rodning; Joseph Newton
Journal:  Avian Dis       Date:  2010-03       Impact factor: 1.577

5.  Protective efficacy of a single dose of baculovirus hemagglutinin-based vaccine in chickens and ducks against homologous and heterologous H5N1 virus infections.

Authors:  Eun Hye Park; Byung Min Song; Jung Yum; Ji An Kim; Seung Kyoo Oh; Hyun Soo Kim; Gil Jae Cho; Sang Heui Seo
Journal:  Viral Immunol       Date:  2014-09-11       Impact factor: 2.257

6.  Generation of a reassortant avian influenza virus H5N2 vaccine strain capable of protecting chickens against infection with Egyptian H5N1 and H9N2 viruses.

Authors:  Ahmed Kandeil; Yassmin Moatasim; Mokhtar R Gomaa; Mahmoud M Shehata; Rabeh El-Shesheny; Ahmed Barakat; Richard J Webby; Mohamed A Ali; Ghazi Kayali
Journal:  Vaccine       Date:  2015-11-25       Impact factor: 3.641

7.  H5N2 avian influenza outbreak in Texas in 2004: the first highly pathogenic strain in the United States in 20 years?

Authors:  Chang-Won Lee; David E Swayne; Jose A Linares; Dennis A Senne; David L Suarez
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Protection of chickens against avian influenza with non-replicating adenovirus-vectored vaccine.

Authors:  Haroldo Toro; De-chu C Tang; David L Suarez; Jianfeng Zhang; Zhongkai Shi
Journal:  Vaccine       Date:  2008-03-17       Impact factor: 3.641

9.  Characterization of influenza virus variants with different sizes of the non-structural (NS) genes and their potential as a live influenza vaccine in poultry.

Authors:  L Wang; D L Suarez; M Pantin-Jackwood; M Mibayashi; A García-Sastre; Y M Saif; C-W Lee
Journal:  Vaccine       Date:  2008-05-22       Impact factor: 3.641

10.  A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates.

Authors:  Haichen Song; Gloria Ramirez Nieto; Daniel R Perez
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.